What is Santhera Pharmaceuticals Holding AG Days Payable?
Santhera Pharmaceuticals Holding AGSPHDF 39 Days Payable is 114.59 as of Dec. 2025, which is 64% below its 10-year median of 319.40. GuruFocus rates SPHDF with a GF Score™ of 39/100 and a GF Value™ of $24.73 (Fairly Valued). The stock has 7 warning signs investors should review. Among 708 Biotechnology companies, Santhera Pharmaceuticals Holding AG ranks worse than 56.36% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG Days Payable Chart
SPHDF vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's Days Payable falls into.
Santhera Pharmaceuticals Holding AG Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (SPHDF) has a Days Payable of 114.59 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. This is 64% below median its historical median of 319.40. Over the past decade, Santhera Pharmaceuticals Holding AG's Days Payable has ranged from 56.90 to 469.68. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #399 out of 708 companies in the Biotechnology industry, placing it in the top 56.4%.
Is Santhera Pharmaceuticals Holding AG's Days Payable too high?
Santhera Pharmaceuticals Holding AG's current Days Payable of 114.59 is 64% below median its 10-year median of 319.40. Over the past 10 years, this metric has ranged from a low of 56.90 to a high of 469.68. The Biotechnology industry median Days Payable is 113.56. Santhera Pharmaceuticals Holding AG's value of 114.59 is 0.9% above this industry median. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #399 out of 708 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #399 out of 708 companies for Days Payable. This places Santhera Pharmaceuticals Holding AG in the lower half of its industry. The industry median Days Payable is 113.56. Santhera Pharmaceuticals Holding AG's value of 114.59 is 0.9% above this benchmark. Historically, Santhera Pharmaceuticals Holding AG's own Days Payable has ranged from 56.90 to 469.68 over the past decade. While the company's 10-year median is 319.40 vs. the industry median of 113.56, Santhera Pharmaceuticals Holding AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 708 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santhera Pharmaceuticals Holding AG's current Days Payable of 114.59 is 0.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Santhera Pharmaceuticals Holding AG and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santhera Pharmaceuticals Holding AG's current Days Payable is 114.59, which is 64% below median its own 10-year median of 319.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG (SPHDF) is currently considered Fairly Valued. The stock's GF Value™ is $24.73, compared to a current price of $23.25 — trading 6% below its estimated fair value. The current Days Payable is 114.59, which is 64% below median its 10-year median of 319.40 and 0.9% above the Biotechnology industry median of 113.56. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current Days Payable is 114.59 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 6% below its estimated GF Value™ of $24.73.
GuruFocus considers Santhera Pharmaceuticals Holding AG to be Fairly Valued.
Key valuation signals for SPHDF:
Days Payable: 114.59 (64% below median its 10-year median of 319.40)
GF Value™: $24.73 vs. price of $23.25 (6% below fair value)
Industry Position: 0.9% above the Biotechnology median (#399 of 708)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG Business Description
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
39GF Score
Get the complete analysis for SPHDF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
